Canopy Growth Confronts Legal Hurdle Amid Operational Turnaround

Canopy Growth certified for securities class action in Canada while nearing profitability. The cannabis firm reports its smallest-ever EBITDA loss and integrates MTL Cannabis acquisition.

A Canadian court has certified a securities fraud class action against Canopy Growth Corp., introducing fresh legal uncertainty just as the cannabis producer shows tangible progress toward profitability. The Ontario Superior Court of Justice authorized the lawsuit, which covers the period from June 1, 2021, to June 22, 2023, and alleges misleading statements by the company and former executives. KND Complex Litigation is representing the plaintiffs.

This action adds to existing legal pressures, including a separate U.S. class action managed by the Rosen Law Firm. That case focuses on a later timeframe and accusations of concealed production costs related to Claybourne pre-rolls and Storz & Bickel devices, alongside claims of exaggerated margin projections.

Despite the legal cloud, Canopy Growth's operational metrics are improving. The company recently reported quarterly revenue of CAD 74.5 million, surpassing expectations. More significantly, its adjusted EBITDA loss shrank to just CAD 3 million, the smallest deficit in its history. Management has set a clear target of achieving positive adjusted EBITDA for the fiscal year 2027.

The stock's performance reflects a disconnect between these operational strides and market sentiment. Shares closed Friday at CAD 1.57 on the Toronto exchange and $1.14 on the NASDAQ. The price remains below its 200-day moving average of CAD 1.65, underscoring a medium-term downtrend. Canopy Growth's market capitalization stands at approximately CAD 664 million.

Wall Street analysts offer a mixed but increasingly constructive view. The average price target sits at CAD 1.97. Canaccord Genuity maintains a "Speculative Buy" rating with a CAD 2.00 target, while ATB Cormark recently upgraded the stock to "Outperform" with a CAD 1.40 target. In contrast, Sanford C. Bernstein reduced its target from CAD 5.30 to CAD 2.50.

A major strategic shift is the completed acquisition of MTL Cannabis in March 2026. The combined entity is poised to become Canada's leading medical cannabis business by revenue, with expected synergies of roughly CAD 10 million to be realized within 18 months. The upcoming Q4 report for fiscal 2026, tentatively scheduled for May 29, will provide the first consolidated results including MTL's contribution.

Concurrent with this integration, a key leadership change is now official. As of early April, David Männer has taken the helm at the Storz & Bickel vaporizer subsidiary, replacing co-founder Jürgen Bickel after 25 years. Männer, a 14-year company veteran, is tasked with accelerating U.S. growth and innovation for the brand.

The path forward hinges on executing this complex strategy while managing legal distractions. With the next earnings report on the horizon, investors will scrutinize whether the operational turnaround can finally outweigh the mounting legal and market pressures.